Summarized by Masters of Longevity from FDA - Drugs.
GLP‑1 therapy supply and compounding policy developments — a concise explainer about updated FDA guidance and what readers should expect next.
Key Takeaways
- The FDA declared the tirzepatide injection shortage resolved after supply normalized nationally.
- The agency issued clarified policies for compounders concerning GLP-1 therapies to ensure appropriate compounding practices.
- The resolution addresses a shortage that began in 2022 driven by elevated demand for GLP-1 medications.
